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Key messages:  
 There are no randomised controlled trials comparing the development of macrolide resistance 
in Mycoplasma genitalium infection between azithromycin 1g with azithromycin 1.5g over 5 
days.  
 Azithromycin 1g treatment is associated with 13.9% (7.7-20.1%) rate of failure and 12.0% 
(7.1-16.9%) risk of macrolide antimicrobial resistance.  
 There is moderate but conflicting evidence that the 5 day regimen may be more effective and 
less likely to cause resistance. 
 The difference in failure and resistance rates is 9.7% (95% CI: 4.3-15.0%, p=0.012) and 8.5% 
(95% CI: 3.2-13.8%, p=0.027) respectively. 
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Abstract 
Background: There is increasing evidence that azithromycin 1g is driving the emergence of 
macrolide resistance in M. genitalium worldwide.  We undertook a meta-analysis of Mycoplasma 
genitalium treatment studies using azithromycin 1g single dose, and azithromycin 500 mgs on day one 
then 250mgs daily for 4 days (5 day regimen) to determine rates of treatment failure and resistance in 
both regimens. 
 
Methods: The online databases PubMed and Medline were searched using terms “Mycoplasma 
genitalium”, “macrolide” or “azithromycin” and “resistance” up to April 2016. Studies were eligible 
if they: used azithromycin 1g or 5 days, assessed patients for macrolide resistant genetic mutations 
prior to treatment, and patients who failed were again resistance genotyped. Random effects meta-
analysis was used to estimate failure and resistance rates. 
 
Results: Eight studies were identified totaling 435 patients of whom 82 (18.9%) had received the 5 
day regimen. The random effects pooled rate of treatment failure and development of macrolide 
antimicrobial resistance mutations with azithromycin 1g was 13.9% (95% Confidence Interval: 7.7-
20.1%) and 12.0% (7.1-16.9%) respectively. Of individuals treated with the 5 day regimen, with no 
prior doxycycline treatment, fewer 3.7% (95% CI: 0.8-10.3, p=0.012) failed treatment, all of whom 
developed resistance (p=0.027).  
 
Conclusion: Azithromycin 1g is associated with high rates of treatment failure and development of 
macrolide resistance in M. genitalium infection with no pre-existing macrolide mutations. There is 
moderate but conflicting evidence that the 5 day regimen may be more effective and less likely to 
cause resistance. 
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Mycoplasma genitalium (MG) is an important, emerging sexually transmitted infection (STI) which 
causes 15-25% of acute non-gonococcal urethritis (NGU) in men and probably causes cervicitis, 
pelvic inflammatory disease, spontaneous abortion, preterm birth and tubal factor infertility in 
women.[1-3]   
 
It is a relatively common ano-genital infection, with the majority of those infected being 
asymptomatic.[1, 3] About 1-3% of men and women in the general population are infected.[4-7]  MG 
is detected more often in those infected with chlamydia, with 3-9% testing positive.[4-9]   
 
Effective management strategies have been hampered not only by  the lack of commercially available 
NAAT assays which have been evaluated to US Food and Drug Administration (FDA) approval 
standard combined with only limited validation for those assays which have been CE marked[1-2],  
but also by the poor treatment efficacy in eradicating MG with doxycycline 100mg twice a day for 7 
days, or azithromycin 1g single dose which are the current first line treatments for NGU and cervicitis 
in the United Kingdom and the United States.[2, 10] Failure to eradicate MG with 7 days doxycycline 
100mgs twice a day occurs in >50% of cases, and in 0-60% of cases treated with azithromycin 1g.[1, 
11-13] Failure rates with azithromycin 1g have increased with time and a recent randomised 
controlled trial found no significant difference in treatment failure between azithromycin 1g and 
doxycycline 100mg twice a day for 7 days (40% vs 30%) .[13] This is probably due to the emergence 
of macrolide antimicrobial resistance in MG, worldwide.[1, 11-12, 14] A number of experts believe 
this may be a consequence of extensive use of azithromycin 1g for the treatment of STIs, as this 
regimen has been demonstrated to cause drug resistance in treatment failures.[1, 2, 11] An extended 5 
day regimen of azithromycin 500mg on day one then 250mg daily  for 4 days was introduced in the 
1990s for the treatment of MG and has been demonstrated by two groups to have high efficacy  
(>95%) and until recently had not been associated with  macrolide resistance.[15-17] 
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There was no information on risk of developing macrolide drug resistance with either azithromycin 1g 
or 1.5g extended regimen in wild type infections when compiling the 2015 United Kingdom NGU 
management guidelines.[18] Expert opinion was divided about discontinuing azithromycin 1g as first 
line treatment in favour of doxycycline 100mgs bd 7 days and/or changing to the azithromycin 
extended 5 day regimen for first line treatment. There are no randomised trials comparing 
azithromycin 1g to the 5 day regimen and the evidence supporting such a change was considered 
weak and no recommendation was made. A recent review by Manhart et al. noted that although the 
evidence was suggestive of slower emergence of resistance with the extended dose, the evidence was 
weak and further data was needed.[13] Undertaking a randomised controlled trial to demonstrate this 
would take 5-7 years to publish its findings and would be complicated by the high rates of MG 
macrolide antimicrobial resistance observed worldwide (13-100%).[3] We therefore undertook a 
review of the literature to determine treatment failure and macrolide resistance rates for patients 
without pre-treatment macrolide resistant genotype infections, using both the single dose 
azithromycin 1g regimen, and a 5 day 1.5g regimen. We also compared the treatment efficacies of 
both treatment regimens.  
 
METHODS 
Search Strategy 
We undertook a review of the literature using the electronic online databases PubMed and Medline to 
identify published articles including the search terms “Mycoplasma genitalium” AND (“macrolide” 
OR “azithromyicin”) AND “resistance” up to April 2016. Eligible studies were English Language 
prospective or retrospective treatment studies using azithromycin 1g or 500mg on day one then 
250mg daily for 4 days, in which patients who failed treatment were assessed for MG macrolide 
resistant genetic mutations prior to, and after treatment. Both men and women were included.  
Women and men were combined for the purposes of the analyses. Macrolide antimicrobial resistance 
was defined as MG with a known macrolide resistance genotype involving a mutation at the 
nucleotide position 2058 (2071) and/or 2059 (2072) in the 23S rRNA gene.[12, 19] Patients were 
excluded from the primary analysis if there was no information on the pre-treatment specimen 23S 
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rRNA macrolide genotype or if they had been pre-treated with doxycycline. A secondary analysis was 
performed to include patients pre-treated with doxycycline as many patients will have received this as 
first line treatment for symptomatic NGU in Europe, prior to extended azithromycin.[2] 
 
Data extraction and outcome 
Identified studies were reviewed by KB, FG and PH and those meeting the inclusion criteria selected.  
Data was extracted by PH and FG and reviewed by SI for rates of failure and rates of macrolide 
resistance after treatment for MG with a course of azithromycin, in patients with macrolide-
susceptible pre-treatment samples. These were defined as the percentage of individuals who returned 
for a test of cure who received a positive MG nucleic acid amplification test (NAAT), and of those 
who were still positive, the percentage who were found to have a macrolide resistance mutation in the 
23S rRNA gene, respectively.  
 
Analysis 
We combined the data to determine the absolute rates of treatment failure and development of 
resistance of the two regimens. Rates of failure and resistance to the 1g regimen were quite variable 
across the different studies and therefore we next took a meta-analytic approach. With this approach 
we calculated the I2 statistics to assess the percentage of variability in treatment failure and 
development of antimicrobial resistance estimates that could be attributed to underlying study 
heterogeneity rather than chance alone. If I2 > 25% random effects meta-analysis was used to estimate 
the pooled rate of macrolide resistance development and if I2 <25% fixed effects meta-analysis.[11, 
20] Both fixed effects and random effects meta-analysis were undertaken. 
We compared the absolute rates of treatment failure and development of resistance between the two 
regimens. We then assessed the differences in these rates and calculated the associated 95% 
confidence intervals (95% CI) and p-values for the difference using Fisher’s exact test. As there were 
only 2 studies which had both data on the 1g and 5 day regimens we performed a sensitivity analysis 
where we only considered the difference in rates between the 2 regimens in these 2 studies. This 
sensitivity analysis helps to avoid the problem of heterogeneity across the studies and provides a more 
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conservative estimate of the difference between the 2 regimens. We also undertook a separate 
sensitivity analysis including the additional patients treated with the 5 day regimen who had been pre-
treated with doxycycline as it is possible prior treatment could have an effect on azithromycin 
efficacy. There were insufficient numbers to separately examine whether gender, age, symptoms or 
study type affected treatment outcome. 
 
Data were analysed using Stata version 13.1 (StataCorp, College Station, TX, USA). 
 
RESULTS 
Study selection and characteristics 
The review process is shown in figure 1. Seventy nine papers were identified and eight treatment 
studies met the inclusion criteria, (Table).[15, 17, 19, 21-26] Five were studies of patients tested for 
MG who were unselected or had NGU, cervicitis, and/or PID and/or were sexual contacts of infected 
partners and treated with azithromycin.[15, 19, 21-23] One was a study of a random sample of men 
with NGU treated with azithromycin 1g who were identified as MG-positive.[24, 25] One was a 
female only study designed to test incidence, organism load, and treatment failure after treatment with 
azithromycin 1g.[26] One was a prospective longitudinal cohort study comprising an observational 
study and a randomized treatment trial involving both men and women.[17] In only three studies was 
there information on the use of the extended azithromycin regimen 500mg then 250mg daily 4 
days.[15, 17, 22]  
 
Azithromycin efficacy 
Four hundred and thirty-five individuals were identified of whom eighty-two (18.9%) had been 
treated with the extended 5 day regimen and 353 (81.1%) were treated with azithromycin 1g, (Table ). 
Of individuals treated with azithromycin 1g, 47 (13.3%, 95% CI: 9.9-17.3%) remained MG-positive 
and of those 43 (91.5%, 95% CI: 80.0-97.6%) had a detectable mutation consistent with macrolide 
antimicrobial resistance. Of 82 individuals treated with the 5 day regimen, only 3 (3.7%: 95% CI: 0.8-
10.3) failed and had a detectable mutation consistent with macrolide antimicrobial developed 
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resistance, which gave a difference in failure and resistance rate compared to 1g of 9.7% (95% CI: 
4.3-15.0%, p=0.012) and 8.5% (95% CI: 3.2-13.8%, p=0.027). 
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Table Details of study type, follow-up and treatment outcomes 
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Study 
Study type, 
setting and year 
of data collection  
Number of 
patients 
treated with 
the 
azithromycin 
5 day 
regimen: 
number (%) 
who did not 
re-attend for 
test of cure 
Number of 
patients 
treated with 
azithromycin 
1 g  and: 
number (%) 
who did not  
re-attend for 
test of cure  
Number 
eligible 
for 
inclusion# 
Time to 
test of 
cure 
Specimen type Treated with 5 day regimen Treated with 1g regimen 
   Total Failure Resistance 
post-
treatment 
Total Failure Resistance 
post-
treatment 
Anagrius 
201315 
Retrospective 
case note study of 
patients with MG.  
Swedish STD 
clinic. 1998-2005 
72 male and 
35 female: 9 
(25.7%) 
72 male and 
22 female: 17 
(12.7%)  
139 Up to 52 
weeks 
Urethral swabs 
male and cervical 
swabs female  
25 0 (0%) 0 (0%) 114* 7* 
(6.1%) 
7* (6.1%) 
Falk 
201517 
Prospective 
longitudinal 
cohort study 
comprising an 
observational 
study and a 
randomized 
treatment trial. 
Swedish STD 
clinics. 2010-
2014 
25 male and 
37 female: 9 
(14.5%) 
10 male and 5 
female: 2 
(13.3%) 
56 Up to 26 
days 
Urine male and 
cervical swabs 
female  
46 3 
(6.5%) 
3 (6.5%) 10 1 
(10.0%) 
1 (10.0%) 
Gesink 
201622 
Prospective, 
cross-sectional 
study  of patients 
with MG.  
Toronto Sexual 
Health Clinic. 
2013 
12 male and 6 
female: 3 
(16.6%) 
 11 2-4 
weeks 
Urine male and 
female  
 
11 0 (0%) 0 (0%) 0   
Bissessor 
201523 
Prospective 
cohort study  of 
 160 (male 
and female)£: 
99 2-4 
weeks 
Urine male and 
genital tract 
0   99 11 
(11.1%) 
11 (11.1%) 
Table 1. Description of studies with details of treatment outcomes 
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patients with MG.  
Melbourne Sexual 
Health Centre. 
2012-2013 
5(3.1%) swabs (high 
vaginal or 
cervical) female  
Couldwell 
201319 
Retrospective 
case note study  
of patients with 
MG.  Western 
Sydney Sexual 
Health Centre. 
2008-2011 
 32 male and 1 
female^ (34 
episodes): 8 
(23.5%)   
12 Median 
46 days 
(12-273 
days) 
urine or urethral 
swab 
 
0   12 4 
(33.3%) 
3 (25%) 
Ito 201125 Retrospective 
case note study of 
men with MG-
positive  NGU.  
Urologic clinic in 
Sendai, Japan. 
2006-2008 
 
 24 male:& 24 2-4 
weeks 
Urine 
 
0   24 7(29.2%) 4 (16.7%) 
Twin 
201221 
Retrospective 
audit of MG- 
positive patients 
who returned for a 
test of cure.  
Melbourne Sexual 
Health Centre. 
2007-2009  
 
 
 
 
 
 
 25 female and 
86  males:$ 
66 Median 
30 days 
(14-127 
days) 
urine or urethral 
swab men and 
cervical swab 
female  
0   66 14 
(21.2%) 
14 (21.2%) 
Walker 
201326 
Prospective 
cohort study of 
patients with MG.  
Australian 
primary care 
clinics. 2007-
 41 female: 9 
(21.9%) 
28 4 weeks Vaginal swab 
 
0   28 3 
(10.7%) 
3 (10.7%) 
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# Number of eligible study participants who had no pre-existing macrolide resistance mutations prior to treatment (see methods); * 3 additional patients 
who experienced treatment failure were excluded due to missing or inconclusive pre-treatment samples;   £Of the 155 patients re-attending 112 (72.3%) 
were male; ^53 patients were diagnosed with MG infection.  & Unclear how many men re-attended and tested negative; $ The number of MG-positive 
patients treated with azithromycin 1 g who did not re-attend for a test of cure is not detailed.  
 
 
 
 
2008 
Total    435   82 3 
(3.7%) 
(95% 
CI: 
0.8-
10.3) 
3 (3.7%)  
(95% CI: 
0.8-10.3) 
353 47 
(13.3%) 
(95% 
CI: 9.9-
17.3) 
43 
(12.2%) 
(95% CI: 
9.0-16.1) 
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The forest plot for treatment failure and antimicrobial resistance with azithromycin 1g is shown in 
figure 2a and b, respectively with details of the fixed effect and random effects meta-analyses. The I2 
value was 60.5% and 41.5% respectively which indicates moderate heterogeneity between effect 
estimates from different studies. The random effects pooled rate of treatment failure and development 
of macrolide antimicrobial resistance mutation(s) with azithromycin 1g was 13.9% (7.7-20.1%) and 
12.0% (7.1-16.9%) respectively. 
 
Of those with pre-treatment macrolide resistance mutations 1 of 1 failed the 5 day regimen[15] and 49 
of 56,[23] 0 of 2,[26] 12 of 16,[21] 6 of 6,[19] 0 of 1[25] and 8 of 10[17] failed azithromycin 1g. Thus 
76 of 92 (82.6% 95% CI 73.3% -89.7%) individuals with a macrolide resistance mutation failed 
treatment with azithromycin.  
 
Sensitivity analyses 
We calculated the differences restricted to the Anagrius et al. and Falk et al. studies and including the 
3 men who had previously been excluded due to missing or inconclusive pre-treatment samples.[15, 
17] This gave a difference in failure and resistance rate of 4.4% (95% CI: -0.02-11.2%, p=0.38) for 1g  
compared to the 5 day regimen. 
 
We also undertook a separate analysis including the additional 56 patients treated with the 5 day 
regimen who had been pre-treated with doxycycline. Of 138 individuals treated with the 5 day 
regimen, no additional failures were observed. Thus 3 (2.2%: 95% CI: 0.5-6.2%) failed and developed 
resistance, an 11.1% (95% CI: 6.8-15.4%, p=0.0001) difference in failure rate and a 10.0% (95% CI: 
5.8-14.2%, p=0.0002) difference in macrolide resistance rate compared to the 1g regimen.  
 
DISCUSSION  
This meta-analysis provides good evidence that an azithromycin 1g regimen is associated with rates 
of failure of 13.9% (7.7-20.1%), and of macrolide resistance of 12.0% (7.1-16.9%) in MG uro-genital 
infection in which no pre-existing macrolide resistance mutations are present. Although fewer 
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treatment failures were observed with the 5 day regimen in individuals with no prior doxycycline 
treatment, data from only three studies was available.[15,17,22] When combining the data in a crude 
way, this equates to a difference in failure rate of 9.7% (95% CI: 4.3-15.0%, p=0.012) and a 
difference in resistance rate of 8.5% (95% CI: 3.2-13.8%, p=0.027), which provides moderate 
evidence of a difference.  Individuals with a pre-existing macrolide 23S rRNA gene mutation had a 
treatment failure rate of 82.6% (95% CI 73.6 -89%). These data are consistent with the hypothesis that 
the use of azithromycin 1g is driving the increase in prevalence of macrolide resistant MG 
genotypes.[11-12] 
 
This is the first meta-analysis of the literature on azithromycin 1g treatment studies of MG to include 
only individuals in whom there was no evidence of a macrolide resistance genotype prior to treatment, 
and hence determine the rate of resistance in fully sensitive isolates. Eight studies of whom only 4 
were prospective [17, 22, 23, 26] were identified and none involved a direct comparison of the two 
regimens. The latest a person could be included as a re-attendance ranged from 26-28 days for the 
four prospective studies [17, 22, 23,2 6] but varied considerably in the four retrospective studies with 
a range of 28-364 days.[15, 19, 21, 25]. In the four prospective studies the loss to follow-up ranged 
from 3-22% [17, 22, 23, 26] which was in general  lower than  the four retrospective studies with a 
range of 12% to 26% in two studies and unknown in the other two.[15, 19, 21, 25] As only those 
individuals who returned for a repeat test were included in this meta-analysis there are two potential 
biases. First, it is conceivable that a higher proportion of treatment failures were included in the 
outcomes, because it is likely, particularly in the retrospective studies, that patients successfully 
treated are less likely to return. Although Ito et al. observed that 3 out of 7 men who retested positive 
were asymptomatic.[25] Second, with a longer duration of follow-up it is possible that some patients 
who re-tested positive were actually re-infections. Only patients with no previous doxycycline 
treatment were included in the primary analysis as doxycycline could reduce the MG load and thus 
the potential for pre-existing micro-organisms containing macrolide resistance mutations.[12, 14, 27] 
Only three studies were identified  with the 5 day regimen which precluded a rigorous meta-analysis 
of the efficacy of this regimen.[15, 17, 22] Finally some individuals who failed treatment and were 
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macrolide resistant did not have suitable pre-treatment specimens for resistance testing and were 
excluded from the analysis. As a sensitivity analysis we calculated the differences restricted to the 
Anagrius et al. and Falk et al. studies and including the 3 men who had previously been excluded due 
to missing or inconclusive pre-treatment samples.[15, 17] The study by Anagrius et al. was 
undertaken in specimens collected from 1998 to 2005. In 2006 no macrolide resistance mutations 
were detected in any MG-positive patients.[17] Including these individuals and comparing the 
treatment regimens in the only two studies which contained data on both the 1g  and 5 day regimens 
also demonstrated a reduction in failure and resistance rates of 4.4% (95% CI: -0.02-11.2%, p=0.38).  
 
Lau et al. recently undertook a systematic review and meta-analysis of azithromycin 1g treatment 
studies and demonstrated increasing failure rates which they attributed to emerging macrolide 
resistance over time.[11] Notably prior to 2009 the pooled treatment efficacy was 85.3% (82.3-
88.3%), similar to 86.1% we observed in individuals with no prior macrolide resistance, and 67% 
(57.0-76.9%) after 2009. This is consistent with an increasing prevalence of macrolide antimicrobial 
resistance due to the widespread use of azithromycin 1g for treating urogenital tract chlamydia 
infection and its associated diseases, non-gonococcal urethritis (NGU) and cervicitis.[3, 11] A 
previous study by Bjornelius et al.  demonstrated high efficacy (96%) of the extended 5 day 
azithromycin regimen and similar failure rate (14%) of azithromycin 1g to the pooled efficacy from 
our meta-analysis and that observed in all studies prior 2009.[11, 16] However, all patients receiving 
the 1g azithromycin regimen were Norwegian. Although no information on antimicrobial resistance is 
available, the study was undertaken in Norway and Sweden between 2002 and 2004. No macrolide 
resistance was identified in Sweden in 2006 but Norway had a 20-30% macrolide failure rate in 2005-
6, which may explain the failure rate in the Norwegian patients.[15, 28] Two subsequent 
observational studies, which did not test for macrolide resistance prior to treatment, one from Norway 
undertaken 2005-2006[28] and one from Australia 2009-13[29] did not observe any difference in 
treatment efficacy between the azithromycin 1g and an extended 5 day regimen, 79% and 70%, 67% 
and 74% respectively. However, these findings could be explained by the presence of macrolide 
resistant micro-organisms in the population prior to treatment; the efficacy of both regimens is 
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effected in macrolide-resistant isolates.[1, 28] Recently Read et al in a retrospective observational 
study found that 4/34 (12% 95% CI 3–27%) patients with wild type infection had macrolide post 
treatment mutations with the azithromycin extended 5 day regimen.[30] The duration of follow-up 
was median 36 days (14-100 days) with a loss to follow-up of 63 (37%) of 169 men.  Although they 
remark the macrolide mutation rate was similar to an historical control treated with azithromycin 1g 
and it is similar to the 12.0% from this meta-analysis there are a number of possible explanations for 
the apparent conflict with our findings. The confidence limits are wide and these are within the 95% 
CI for the macrolide post mutation rate observed in this analysis 3.7% (95% CI: 0.8-10.3) and may 
just be a chance observation related to the small size of the study. In addition, given the high loss to 
follow-up it is possible that the actual macrolide post treatment mutation rate was lower. Third, 
macrolide resistance was associated with men who have sex with men (MSM). This group was highly 
sexually active with a median of 3(2–6) sexual partners in the last 3 months prior to treatment. 
Seventy six percent of MG isolates were macrolide resistant in the local MSM population and 
although review of the notes suggested that re-infection was not the cause this remains a possibility as 
it was not a prospective study. Finally, an alternative but not mutually exclusive explanation is that in 
populations with high level of resistance mixed infections, not detected with the current 
methodologies, would tend to contribute to apparent resistance development. Taken together the 
conclusion of Read et al that the extended azithromycin 1.5g was no more effective than a single 1g 
dose should be viewed with caution and highlights the need for further high quality prospective 
studies using this regimen.[30] When the data from the Read study is added to this study and 
combined in a crude way  no difference is observed between Azithromycin 1g and the extended 
regimen in post treatment macrolide mutations (p=0.09) but remains significantly different when 
patients with prior doxycycline are included (p=0.005). 
 
Interestingly even in the presence of macrolide antimicrobial resistance our findings suggest 17% of 
individuals will test negative following treatment with azithromycin. This might be explained by other 
factors including either a temporary suppression of the infection and/or spontaneous fluctuations in 
the MG load which could lead to DNA shedding below the limit of detection, resulting in false 
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negatives.[17] In addition, four studies have observed spontaneous clearance of MG [31-34] 
suggesting that at least some of these individuals had resolved the infection.  The most likely 
mechanism is the adaptive host immune response as it appears to be important in resolving infections, 
even following successful antimicrobial therapy.[35,36]  
 
The findings provide moderate evidence that the extended 5 day azithromycin regimen (500mgs then 
250mgs od for 4 days) is more effective than azithromycin 1g in treating MG. However we believe 
caution needs to be exercised in using the extended regimen as a replacement for azithromycin 1g and 
all patients followed up to establish that they have been cured as some patients will still fail treatment 
either due to pre-existent macrolide resistance or to its  emergence following treatment and may be 
asymptomatic.[1-3, 25] Interestingly when the 56 patients with prior doxycycline treatment who were 
then treated with the extended regimen are considered, the superiority of the 5 day regimen is more 
pronounced with a 11.1% (95% CI: 6.8-15.4%, p=0.0001) difference in failure rate and a 10.0% (95% 
CI: 5.8-14.2%, p=0.0002) difference in macrolide resistance rate compared to the 1g regimen. This is 
probably as a result of a reduced micro-organism load following doxycycline treatment which will 
bias the comparison of this group with azithromycin 1g.[12, 13, 27] Nevertheless it provides strong 
support for the use of doxycycline 100mgs bd for 7 days as first line treatment in men with NGU, in 
whom MG is a common pathogen, with the extended azithromycin reserved for those who fail 
treatment.[2] There are no treatment studies on using other higher dose extended regimens such as 
azithromycin 1g then 250mgs od for 4 days and it is not possible to comment on whether other 
extended regimens are more efficacious than 500mgs then 250mgs od for 4 days.[2] 
 
There are at least two hypothesis of why macrolide resistance emerges in MG following azithromycin 
1g. The most likely mechanism is heterotypic resistance in which the use of azithromycin selects for 
pre-existing bacteria with macrolide resistance mutations which have arisen as a result of spontaneous 
genetic mutations.[12, 14] If this was the only mechanism both regimens would be expected to have 
similar rates of macrolide resistance following treatment, consistent with the recent finding of Read et 
al.[30] . Alternatively, it is possible that failure to eradicate micro-organisms, before sub- MIC levels 
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of azithromycin develop extracellularly with azithromycin 1g, may be occurring, enabling resistance 
to develop during treatment.[12, 14] Azithromycin 1g is cleared more rapidly from serum and 
extracellular fluid (where MG replicates) than 1.5g.[14, 37] Macrolides are not bactericidal and the 
duration of exposure to above MIC levels of azithromycin in vivo which is required to kill MG is 
unknown.  Both hypotheses would be consistent with the observation that higher organism load prior 
to treatment has been associated with azithromycin 1g treatment failure and the findings from this 
analysis that the extended regimen is likely to be more efficacious.[26]  
 
Conclusion 
This meta-analysis has demonstrated that with wild type MG infection 13.9% will fail treatment with 
azithromycin 1g and 12.0% will develop macrolide resistance. These data are consistent with the 
hypothesis that the use of azithromycin 1g is driving the increase in prevalence of macrolide resistant 
MG genotypes which explains its reduced efficacy since 2009 and its use should be discontinued in 
MG-associated conditions.[1-3, 11] This study provides only moderate evidence that fewer patients 
will fail treatment and develop macrolide resistance with the extended 5 day regimen compared to 
azithromycin 1g which conflicts with the recent findings of  Read et al.[30] An increasing pre-existent 
macrolide resistance, up to 100%, is seen in many countries.[1, 38] Initial doxycycline treatment will 
eradicate 20-40% MG strains, including macrolide resistant strains, reducing the need for 
Moxifloxacin treatment, in addition to possible reduced micro-organism load following doxycycline 
treatment. Further prospective studies comparing the extended azithromycin regimen with single dose, 
and azithromycin treatment following doxycycline are urgently needed. 
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